TARGID

Targid is a biotechnology company focused on the discovery and development of novel therapeutics targeting G protein-coupled receptors (GPCRs) for the treatment of cancer and inflammatory diseases. The company utilizes its proprietary Targid Discovery Platform to identify and validate high-value targets that have been historically difficult to drug. By leveraging advanced structural biology and computational modeling, Targid aims to develop highly selective small molecule inhibitors and modulators. The company's pipeline is currently in the pre-clinical stage, with several programs focused on oncology and immune-mediated conditions.